Valuation: Northwest Biotherapeutics, Inc.

Market Cap 28Cr 24Cr 22Cr 21Cr 39Cr 2.64TCr 39Cr 264.04Cr 103.63Cr 1.32TCr 103.97Cr 101.69Cr 4.41TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 37Cr 32Cr 30Cr 28Cr 52Cr 3.56TCr 53Cr 355.68Cr 139.59Cr 1.77TCr 140.06Cr 136.98Cr 5.94TCr EV / Sales 2026 *
-
EV / Sales 2027 * 10.3x
Free-Float
95.04%
Yield 2026 *
-
Yield 2027 * -
09/07 Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma CI
16/05 Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
21/04 Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic CI
16/04 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
15/04 Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
15/11 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
14/11 Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP CI
31/25/31 Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC CI
27/25/27 Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding CI
24/25/24 Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC. CI
27/25/27 Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million. CI
18/25/18 Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman CI
15/25/15 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day-0.61%
1 week-4.48%
1 month-12.21%
3 months-17.17%
6 months-43.62%
Current year-28.32%
1 week 0.16
Extreme 0.16
0.18
1 month 0.14
Extreme 0.1411
0.2
Current year 0.14
Extreme 0.1411
0.34
1 year 0.14
Extreme 0.1411
0.37
3 years 0.14
Extreme 0.1411
1.09
5 years 0.14
Extreme 0.1411
2.05
10 years 0.14
Extreme 0.14
2.51
Manager TitleAgeSince
Chief Executive Officer 82 01/06/2007
Chief Executive Officer 71 08/06/2011
Chief Tech/Sci/R&D Officer 67 01/01/2000
Director TitleAgeSince
Director/Board Member 82 01/01/1998
Chairman 71 17/05/2007
Director/Board Member 57 01/04/2012
Date Insider Type Main position Quantity % Market Cap.
29/08/24 Don

Founder

10,00,000 0.0826%
09/08/24 Don

Chief Technology Officer

30,00,000 0.2478%
08/08/24 Don

Founder

10,00,000 0.0826%
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%-4.48%-32.87%-69.03% 28Cr
+2.35%+2.74%+33.41%+79.20% 5.65TCr
-0.21%-7.38%+25.34%+63.02% 5.36TCr
-2.44%+1.40%-15.74%-16.80% 2.29TCr
-2.85%-7.78%-8.09%+346.36% 2.14TCr
+2.49%-0.92%+20.31%-12.15% 2.03TCr
+0.79%-1.06%+29.29%-33.32% 1.76TCr
+0.58%-5.88%+16.30%+540.37% 1.47TCr
-5.25%-4.23%+46.41%+169.05% 1.33TCr
+3.41%-6.61%+163.08%+280.43% 1.35TCr
Average -0.17%-3.86%+27.74%+134.71% 2.34TCr
Weighted average by Cap. +0.23%-2.96%+28.60%+119.76%

Financials

2026 *2027 *
Net sales - 3.89Cr 3.38Cr 3.15Cr 2.89Cr 5.46Cr 371.67Cr 5.55Cr 37Cr 15Cr 185.03Cr 15Cr 14Cr 620.44Cr
Net income - -
Net Debt 9.61Cr 8.35Cr 7.77Cr 7.14Cr 13Cr 917.17Cr 14Cr 92Cr 36Cr 456.61Cr 36Cr 35Cr 1.53TCr 12Cr 11Cr 10Cr 9.28Cr 18Cr 1.19TCr 18Cr 119.16Cr 47Cr 593.76Cr 47Cr 46Cr 1.99TCr
Logo Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.
Employees
105
Date Price Change Volume
31/26/31 $0.1640 -0.61% 12,61,005
30/26/30 $0.1650 +1.85% 20,11,696
29/26/29 $0.1620 -5.48% 23,03,171
28/26/28 $0.1714 -1.27% 21,67,426
27/26/27 $0.1736 +1.12% 17,09,184
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1640USD
Average target price
1.000USD
Spread / Average Target
+509.76%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NWBO Stock